Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Sells $1,668,600.00 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 30,000 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $55.62, for a total value of $1,668,600.00. Following the transaction, the chief executive officer now directly owns 196,540 shares of the company’s stock, valued at approximately $10,931,554.80. This trade represents a 13.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

• On Monday, October 14th, Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $46.28, for a total value of $198,680.04.

CRISPR Therapeutics Stock Up 0.9 %

Shares of CRISPR Therapeutics stock opened at $47.25 on Friday. The company’s fifty day simple moving average is $47.88 and its two-hundred day simple moving average is $52.04. The firm has a market cap of $4.03 billion, a PE ratio of -16.70 and a beta of 1.67. CRISPR Therapeutics AG has a 12-month low of $43.42 and a 12-month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The business had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same period in the previous year, the firm earned ($1.41) EPS. As a group, sell-side analysts expect that CRISPR Therapeutics AG will post -5.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CRISPR Therapeutics

Several large investors have recently made changes to their positions in CRSP. Global Trust Asset Management LLC increased its holdings in shares of CRISPR Therapeutics by 150.0% during the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after acquiring an additional 300 shares in the last quarter. Larson Financial Group LLC increased its stake in CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC lifted its stake in shares of CRISPR Therapeutics by 99.7% in the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after buying an additional 307 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of CRISPR Therapeutics during the second quarter valued at approximately $35,000. Finally, Orion Capital Management LLC increased its position in shares of CRISPR Therapeutics by 44.0% during the first quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock valued at $49,000 after acquiring an additional 220 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CRSP has been the topic of a number of research reports. Truist Financial lowered their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday, November 7th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Chardan Capital lowered their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Finally, Stifel Nicolaus cut their price target on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a report on Tuesday, August 6th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $74.94.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.